Glenmark’s FabiFlu Shows Promise for COVID-19 Patients By Sam | July 22, 2020 The drug was generally well tolerated, with no serious adverse events or deaths, the company said. Source: Devices & Diagnostics Letter Posted in Devices & Diagnostics Letter